CTSO Cytosorbents
- 0.968
- +0.101+11.69%
- 0.902
- -0.066-6.78%
Cytosorbents News
B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
B. Riley Securities Reiterates Buy on CytoSorbents, Maintains $3 Price Target
B. Riley Securities analyst Yuan Zhi reiterates CytoSorbents with a Buy and maintains $3 price target.
Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
The following is a summary of the Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript:Financial Performance:Cytosorbents Corporation experienced a 14% increase in product sales in Q1 2024
CytoSorbents (CTSO.US): The 2024 Q1 financial report achieved revenue of $9.787 million, previous value of USD 9.449 million, expected value of USD 9.78 million; earnings per share were -0.12 USD, previous value was -0.17 USD, and expected value was -0.12
CytoSorbents (CTSO.US): The 2024 Q1 financial report achieved revenue of $9.787 million, previous value of USD 9.449 million, expected value of USD 9.78 million; earnings per share were -0.12 USD, previous value was -0.17 USD, and expected value was -0.12 USD.
CytoSorbents Q1 2024 GAAP EPS $(0.12), Inline, Sales $9.787M Beat $9.785M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 29.41 percent increase over losses of $(0.17) per share from the same peri
Cytosorbents | 10-Q: Quarterly report
CytoSorbents: Q1 Earnings Snapshot
Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, Vs. Street Est of $9.79M
04:18 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M
Cytosorbents 1Q Rev $9.79M >CTSO
Cytosorbents 1Q Rev $9.79M >CTSO
Press Release: CytoSorbents Reports First Quarter 2024 Results
CytoSorbents Reports First Quarter 2024 Results -- Product Sales up a robust 14% over prior year, and a significant 22% sequentially -- We believe the STAR-T data presented at AATS suppor
Hold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical Results
CytoSorbents Executives Take Pay Cuts for Stock Options
Cytosorbents Full Year 2023 Earnings: Misses Expectations
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents with a Neutral and maintains $1 price target.
Cytosorbents Financial and Clinical Study Outlook: Maintaining a Hold Rating
Earnings Call Summary | Cytosorbents(CTSO.US) Q4 2023 Earnings Conference
The following is a summary of the CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript:Financial Performance:CytoSorbents Corporation reported a revenue of $36.3 million for the year, a 5%
Recap: CytoSorbents Q4 Earnings
CytoSorbents (NASDAQ:CTSO) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:15 PM.Here's what investors need to know about the announcement.EarningsCytoSorbents beat estimated earnin
CytoSorbents Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $8.700M Miss $9.285M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. The company reported quarterly sales of $8.700 million
Analysis
Price Target
No Data
